EpiVax Signs First Commercial License for Tregitope Technology
PROVIDENCE, R.I., April 25, 2017 - Providence-based biotechnology company EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating ...
Scientists at EpiVax are expert practitioners of a new discipline – immunoinformatics. We have harnessed the power of immune modulation for the development of improved vaccines and biotherapeutics.
We take pride in our creativity and our ability to put our combined intelligence, experience, and creativity to work to improve human health. Open minds, creative thought and natural curiosity lead to paradigm shifts.